---
title: "Akeso says China NMPA clears Phase I trial for B7-H3 ADC AK157D1 in solid tumors"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296571352.md"
description: "Akeso has received clearance from China's NMPA CDE to initiate a Phase I clinical trial for AK157D1, a B7-H3 antibody-drug conjugate (ADC), in patients with advanced solid tumors. This development marks the third next-generation ADC candidate to enter clinical testing for Akeso, reinforcing its oncology strategy focused on IO2.0 and ADC2.0 platforms."
datetime: "2026-08-21T05:31:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296571352.md)
  - [en](https://longbridge.com/en/news/296571352.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296571352.md)
generator: "portal-rs"
---

# Akeso says China NMPA clears Phase I trial for B7-H3 ADC AK157D1 in solid tumors

-   Akeso secured China NMPA CDE clearance to start a Phase I trial of AK157D1, a B7-H3 antibody-drug conjugate, in advanced solid tumors. \* The candidate becomes Akeso’s third next-generation ADC to enter clinical development, supporting its IO2.0 and ADC2.0 oncology strategy. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akeso Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608210130PR\_NEWS\_USPR\_\_\_\_\_CN31197) on August 21, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [09926.HK](https://longbridge.com/en/quote/09926.HK.md)

## Related News & Research

- [Aikobio’s AK0406 flu prevention drug wins China IND clearance for clinical trials](https://longbridge.com/en/news/296204995.md)
- [Akeso secures China NMPA authorisation for ivonescimab combo](https://longbridge.com/en/news/295783324.md)
- [CStone says China NMPA clears IND for CS5007 EGFR/HER3 bispecific ADC](https://longbridge.com/en/news/296540686.md)
- [AKESO  Yidafang's Third Indication NDA Approved](https://longbridge.com/en/news/295687122.md)
- [Akeso says press release available on Phase II dosing of AK146D1 with ivonescimab in advanced NSCLC](https://longbridge.com/en/news/293166112.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**